Molecular docking studies of quercetin and its analogues against human inducible nitric oxide synthase

SpringerPlus

Volumn 1, Issue 1, 2012, Pages 1-10

  Singh, Salam Pradeep ^a   Konwar, Bolin Kumar ^a  

^a TEZPUR UNIVERSITY   (India)

Author keywords

Analogues; Cancer; Inducible iNOS; Molecular docking; Molecular modification

Indexed keywords

EID: 84876423515     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-1-69     Document Type: Article

References (64)

1. Aaltoma SH, Lipponen PK, Kosma VM (2001) Inducible nitric oxide synthase (iNOS) expression and its prognostic value in prostate cancer. Anticancer Res 21:3101-3106
2. Aaltomaa SH, Lipponen PK, Viitanen J, Kankkunen JP, Ala-Opas MY, Kosma VM (2000) The prognostic value of inducible nitric oxide synthase in local prostate cancer. BJU Int 86:234-239
3. Advanced Chemistry Development, Inc (1994) ACD/ I-Lab, Version 2.0., Toronto, ON, Canada
4. Ambs S, Merriam WG, Bennett WP, Felley-Bosco E, Ogunfusika MO, Oser SM, Klein S, Shields PG, Billiar TR, Harris CC (1998a) Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res 58:334-341
5. Ambs S, Merriam WG, Ogunfusika MO, Bennett WP, Ishibe N, Hussain SP, Tzeng EE, Geller DA, Billiar TR, Harris CC (1998b) p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat Med 4:1371-1376
6. Ambs S, Bennett WP, Merriam WG, Ogunfusika MO, Sean MO, Harrington AM, Shields PG, Felley-Bosco E, Hussain SP, Harris CC (1999) Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst 91:86-88
7. Bolton E, Wang Y, Thiessen PA, Bryant SH (2008) PubChem: integrated platform of small molecules and biological activities, 4th edn, Annual reports in computational chemistry. American Chemical Society, Washington, DC, chapt 12
8. Brennan PA, Moncada S (2002) From pollutant gas to biological messenger: the diverse actions of nitric oxide in cancer. Ann R Coll Surg Engl 84:75-78
9. ChemOffice (2010) CambridgeSoft Corporation, 875 Massachusetts Ave, Cambridge, MA 02139, USA
10. Chen YC, Shen SC, Lee WR, Hou WC, Yang LL, Lee TJ (2001) Inhibition of nitric oxide synthase inhibitors and lipopolysaccharide induced inducible NOS and cyclooxygenase-2 gene expressions by rutin, quercetin, and quercetin pentaacetate in RAW 264.7 macrophages. J Cell Biochem 82:537-548
11. Cho HJ, Xie QW, Calaycay J, Mumford RA, Swiderek KM, Lee TD, Nathan C (1992) Calmodulin is a subunit of nitric oxide synthase from macrophages. J Exp Med 176:599-604
12. Crowell JA, Steele VE, Sigman CC, Fay JR (2003) Is inducible nitric oxide synthase a target for chemoprevention? Mol Cancer Ther 2:815-823
13. Fischmann TO, Hruza A, Niu XD, Fossetta JD, Lunn CA, Dolphin E, Prongay AJ, Reichert P, Lundell DJ, Narula SK, Weber PC (1999) Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation. Nat Struct Biol 6:233-242
14. Forrester K, Ambs S, Lupold SE, Kapust RB, Spillare EA, Weinberg WC, Felley-Bosco E, Wang XW, Geller DA, Tzeng E, Billiar TR, Harris CC (1996) Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci USA 93:2442-2447
15. Franchi A, Gallo O, Paglierani M, Sardi I, Magnelli L, Masini E, Santucci M (2002) Inducible nitric oxide synthase expression in laryngeal neoplasia: correlation with angiogenesis. Head Neck 24:16-23
16. Freitas MP (2006) MIA-QSAR modelling of anti-HIV-1 activities of some 2-amino-6-arylsulfonylbenzonitriles and their thio and sulfinyl congeners. Org Biomol Chem 4:1154-1159
17. Gallo O, Masini E, Morbidelli L, Franchi A, Fini-Storchi I, Vergari WA, Ziche M (1998) Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 90:587-596
18. García-Mediavilla V, Crespo I, Collado PS, Esteller A, Sánchez-Campos S, Tuñón MJ, González-Gallego J (2007) The anti-inflammatory flavones quercetin and kaempferol cause inhibition of inducible nitric oxide synthase, cyclooxygenase-2 and reactive C-protein, and down-regulation of the nuclear factor kappaB pathway in Chang Liver cells. Eur J Pharmacol 557:221-229
19. Garthwaite J, Boulton CL (1995) Nitric oxide signaling in the central nervous system. Annu Rev Physiol 57:683-706
20. Gehlhaar DK, Verkhivker G, Rejto PA, Fogel DB, Fogel LJ, Freer ST (1995) Docking Conformationally Flexible Small Molecules Into a Protein Binding Site Through Evolutionary Programming. Proceedings of the Fourth International Conference on Evolutionary Programming. Lect Notes Comput Sci 1447:449-461
21. Gehlhaar DK, Bouzida D, Rejto PA (1998) Fully Automated And Rapid Flexible Docking of Inhibitors Covalently Bound to Serine Proteases. Proceedings of the Seventh International Conference on Evolutionary Programming. Springer-Verlag, London, UK, pp 449-461
22. Ghosh DK, Crane BR, Ghosh S, Wolan D, Gachhui R, Crooks C, Presta A, Tainer JA, Getzoff ED, Stuehr DJ (1999) Inducible nitric oxide synthase: role of the N-terminal beta-hairpin hook and pterin-binding segment in dimerization and tetrahydrobiopterin interaction. EMBO J 18:6260-6270
23. Goodman JE, Hofseth LJ, Hussain SP, Harris CC (2004) Nitric oxide and p53 in cancer-prone chronic inflammation and oxyradical overload disease. Environ Mol Mutagen 44:3-9
24. Griffith OW, Stuehr DJ (1995) Nitric oxide synthases: properties and catalytic mechanism. Annu Rev Physiol 57:707-736
25. Hao XP, Pretlow TG, Rao JS, Pretlow TP (2001) Inducible nitric oxide synthase (iNOS) is expressed similarly in multiple aberrant crypt foci and colorectal tumors from the same patients. Cancer Res 61:419-422
26. Hayashi H, Kuwahara M, Fujisaki N, Furihata M, Ohtsuki Y, Kagawa S (2001) Immunohistochemical findings of nitric oxide synthase expression in urothelial transitional cell carcinoma including dysplasia. Oncol Rep 8:1275-1279
27. Hickey MJ, Granger DN, Kubes P (2001) Inducible nitric oxide synthase (iNOS) and regulation of leucocyte/endothelial cell interactions: studies in iNOS-deficient mice. Acta Physiol Scand 173:119-126
28. James A, Crowell VES, Caroline CS, Judith RF (2003) Is inducible nitric oxide synthase a target for chemoprevention? Mol Cancer Ther 2:815-823
29. Kinaci MK, Erkasap N, Kucuk A, Koken T, Tosun M (2012) Effects of quercetin on apoptosis, NF-κB and NOS gene expression in renal ischemia/reperfusion injury. Exp Ther Med 3:249-254
30. Knowles RG, Moncada S (1994) Nitric oxide synthases in mammals. Biochem J 298:249-258
31. Kojima M, Morisaki T, Tsukahara Y, Uchiyama A, Matsunari Y, Mibu R, Tanaka M (1999) Nitric oxide synthase expression and nitric oxide production in human colon carcinoma tissue. J Surg Oncol 70:222-229
32. Lipinski CA (2008) Drug-like properties and the causes of poor solubility and poor permeability. J Pharm Toxicol Methods 44:235-249
33. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 23:3-25
34. Lirk P, Hoffmann G, Rieder J (2002) Inducible nitric oxide synthase-time for reappraisal. Curr Drug Targets Inflamm Allergy 1:89-108
35. MacMicking J, Xie QW, Nathan C (1997) Nitric oxide and macrophage function. Annu Rev Immunol 15:323-350
36. Marletta MA, Hurshman AR, Rusche KM (1997) Catalysis by nitric oxide synthase. Curr Opin Chem Biol 2:656-663
37. Marrogi AJ, Travis WD, Welsh JA, Khan MA, Rahim H, Tazelaar H, Pairolero P, Trastek V, Jett J, Caporaso NE, Liotta LA, Harris CC (2000) Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 6:4739-4744
38. Massi D, Franchi A, Sardi I, Magnelli L, Paglierani M, Borgognoni L, Maria Reali U, Santucci M (2001) Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions. J Pathol 194:194-200
39. Messmer UK, Ankarcrona M, Nicotera P, Brüne B (1994) p53 expression in nitric oxide-induced apoptosis. FEBS Lett 355:23-26
40. Michal G (1999) Biochemical pathways. John Wiley & Sons, New York
41. Michel T, Feron O (1997) Nitric oxide synthases: which, where, how, and why? J Clin Invest 100:2146-2152
42. Molegro APS (2011) MVD 5.0 Molegro Virtual Docker., DK-8000 Aarhus C, Denmark
43. Murakami A, Ashida H, Terao J (2008) Multitargeted cancer prevention by quercetin. Cancer Lett 269:315-325
44. Peng Y, Deng Z, Wang C (2008) Preparation and prodrug studies of quercetin pentabenzensulfonate. Yakugaku Zasshi 128:1845-1849
45. Rao CV (2004) Nitric oxide signaling in colon cancer chemoprevention. Mutat Res 555:107-119
46. Raso GM, Meli R, Di Carlo G, Pacilio M, Di Carlo R (2001) Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A.1. Life Sci 68:921-931
47. Rietjens IM, Boersma MG, van der Woude H, Jeurissen SM, Schutte ME, Alink GM (2005) Flavonoids and alkenylbenzenes: mechanisms of mutagenic action and carcinogenic risk. Mutat Res 574:124-138
48. Ropponen KM, Kellokoski JK, Lipponen PK, Eskelinen MJ, Alanne L, Alhava EM, Kosma VM (2000) Expression of inducible nitric oxide synthase in colorectal cancer and its association with prognosis. Scand J Gastroenterol 11:1204-1211
49. Sandau K, Pfeilschifter J, Brüne B (1997) The balance between nitric oxide and superoxide determines apoptotic and necrotic death of rat mesangial cells. J Immunol 158:4938-4946
50. Schrödinger LLC (2012) QikProp, version 3.5., New York, NY
51. Swana HS, Smith SD, Perrotta PL, Saito N, Wheeler MA, Weiss RM (1999) Inducible nitric oxide synthase with transitional cell carcinoma of the bladder. J Urol 161:630-634
52. Thomsen R, Christensen MH (2006) MolDock: a new technique for high-accuracy molecular docking. J Med Chem 49:3315-3321
53. Thomsen LL, Lawton FG, Knowles RG, Beesley JE, Riveros-Moreno V, Moncada S (1994) Nitric oxide synthase activity in human gynecological cancer. Cancer Res 54:1352-1354
54. Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S (1995) Nitric oxide synthase activity in human breast cancer. Br J Cancer 72:41-44
55. Ulrich B, Norman LA (1982) Molecular mechanics (ACS Monograph 177). American Chemical Society, Washington, DC
56. Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M, Härkönen P (2001) Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res 29:23-28
57. Vakkala M, Kahlos K, Lakari E, Pääkkö P, Kinnula V, Soini Y (2000) Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. Clin Cancer Res 6:2408-2416
58. van der Woude H, Alink GM, van Rossum BE, Walle K, van Steeg H, Walle T, Rietjens IM (2005) Formation of transient covalent protein and DNA adducts by quercetin in cells with and without oxidative enzyme activity. Chem Res Toxicol 18:1907-1916
59. Verschoyle RD, Steward WP, Gescher AJ (2007) Putative cancer chemopreventive agents of dietary origin-how safe are they? Nature Cancer 59:152-162
60. Wang Y, Bolton E, Dracheva S, Karapetyan K, Shoemaker SA, Suzek TO, Wang J, Xiao J, Zhang J, Bryant SH (2010) An overview of the PubChem BioAssay resource. Nucleic Acids Res 38:D255-D266
61. Weiming X, Li ZL, Marilena L, Mohamed A, Ian GC (2002) The role of nitric oxide in cancer. Cell Res 12:311-320
62. Xu W, Charles IG, Moncada S, Gorman P, Sheer D, Liu L, Emson P (1994) Mapping of the genes encoding human inducible and endothelial nitric oxide synthase (NOS2 and NOS3) to the pericentric region of chromosome 17 and to chromosome 7, respectively. Genomics 21:419-422
63. Yagihashi N, Kasajima H, Sugai S, Matsumoto K, Ebina Y, Morita T, Murakami T, Yagihashi S (2000) Increased in situ expression of nitric oxide synthase in human colorectal cancer. Virchows Arch 436:109-114
64. Yang JM, Chen CC (2004) GEMDOCK: a generic evolutionary method for molecular docking. Proteins 55:288-304